Article Text
Paper
Bone marrow transplantation in the prevention of intellectual disability due to inherited metabolic disease: ethical issues
Abstract
Many inherited metabolic diseases may lead to varying degrees of brain damage and thus also to intellectual disability. Bone marrow transplantation (BMT) has been used for over two decades as a form of secondary prevention to stop or reverse the progress of the disease process in some of these conditions. At the population level the impact of BMT on the prevalence of intellectual disability is minute, but at the individual level its impact on the prognosis of the disease and the well-being of the patient can be substantial. The dark side of BMT use is the burden of side effects, complications and transplantation-related mortality in less successful cases. The ethical issues involved in this therapy are discussed in this review.
Statistics from Altmetric.com
Read the full text or download the PDF:
Other content recommended for you
- Clinical course of sly syndrome (mucopolysaccharidosis type VII)
- Ethical issues related to the access to orphan drugs in Brazil: the case of mucopolysaccharidosis type I
- Haemopoietic stem cell transplantation for genetic disorders
- Mucopolysaccharidosis type I disguised as rickets
- Kenneth Hugh-Jones
- Cardiac issues in adults with the mucopolysaccharidoses: current knowledge and emerging needs
- Hurler syndrome (Mucopolysaccharidosis type I)
- Mucopolysaccharidosis type IVA (Morquio A): a close differential diagnosis of spondylo-epiphyseal dysplasia
- Psychopharmacological treatment of behavioural problems in Sanfilippo syndrome
- Diagnosis and management of ophthalmological features in patients with mucopolysaccharidosis